skip to main content
Idioma:
Primo Search
Clear Search Box
Search in: Busca Geral
Busca Avançada
Busca por Índices

Targeted selection of HIV-specific antibody mutations by engineering B cell maturation

Saunders, Kevin O ; Wiehe, Kevin ; Tian, Ming ; Acharya, Priyamvada ; Bradley, Todd ; Alam, S Munir ; Go, Eden P ; Scearce, Richard ; Sutherland, Laura ; Henderson, Rory ; Hsu, Allen L ; Borgnia, Mario J ; Chen, Haiyan ; Lu, Xiaozhi ; Wu, Nelson R ; Watts, Brian ; Jiang, Chuancang ; Easterhoff, David ; Cheng, Hwei-Ling ; McGovern, Kelly ; Waddicor, Peyton ; Chapdelaine-Williams, Aimee ; Eaton, Amanda ; Zhang, Jinsong ; Rountree, Wes ; Verkoczy, Laurent ; Tomai, Mark ; Lewis, Mark G ; Desaire, Heather R ; Edwards, Robert J ; Cain, Derek W ; Bonsignori, Mattia ; Montefiori, David ; Alt, Frederick W ; Haynes, Barton F

Science (American Association for the Advancement of Science), 2019-12, Vol.366 (6470) [Periódico revisado por pares]

United States: The American Association for the Advancement of Science

Texto completo disponível

Citações Citado por
  • Título:
    Targeted selection of HIV-specific antibody mutations by engineering B cell maturation
  • Autor: Saunders, Kevin O ; Wiehe, Kevin ; Tian, Ming ; Acharya, Priyamvada ; Bradley, Todd ; Alam, S Munir ; Go, Eden P ; Scearce, Richard ; Sutherland, Laura ; Henderson, Rory ; Hsu, Allen L ; Borgnia, Mario J ; Chen, Haiyan ; Lu, Xiaozhi ; Wu, Nelson R ; Watts, Brian ; Jiang, Chuancang ; Easterhoff, David ; Cheng, Hwei-Ling ; McGovern, Kelly ; Waddicor, Peyton ; Chapdelaine-Williams, Aimee ; Eaton, Amanda ; Zhang, Jinsong ; Rountree, Wes ; Verkoczy, Laurent ; Tomai, Mark ; Lewis, Mark G ; Desaire, Heather R ; Edwards, Robert J ; Cain, Derek W ; Bonsignori, Mattia ; Montefiori, David ; Alt, Frederick W ; Haynes, Barton F
  • Assuntos: Activation-induced cytidine deaminase ; Affinity ; AIDS Vaccines - genetics ; AIDS Vaccines - immunology ; Animal models ; Animals ; Antibody Affinity - genetics ; Antibody response ; B-Lymphocytes - immunology ; Binding sites ; CD4 antigen ; Cytidine deaminase ; Design ; Engineering ; env Gene Products, Human Immunodeficiency Virus - genetics ; env Gene Products, Human Immunodeficiency Virus - immunology ; Epitopes - genetics ; Gene Knock-In Techniques ; Glycan ; HIV ; HIV Antibodies - immunology ; HIV-1 - immunology ; Human immunodeficiency virus ; Humans ; Immunization ; Immunoglobulins ; Logical Thinking ; Lymphocytes B ; Macaca ; Maturation ; Mice ; Mice, Mutant Strains ; Monoclonal antibodies ; Mutation ; Neutralization ; Neutralizing ; Nucleotides ; Precursors ; Selection, Genetic ; Strategy ; Vaccination ; Vaccine development ; Vaccines ; Variable region
  • É parte de: Science (American Association for the Advancement of Science), 2019-12, Vol.366 (6470)
  • Notas: Experimental design: K.O.S., K.W., P.A., T.B., S.M.A., F.W.A., M.T., B.F.H. Investigation and assays: A.E., M.T., P.A., B.W., T.B., H.C., X.L., C.J., J.Z., E.G., D.E., A.E., D.W.C., H.L.C., N.R.W., K.M., P.W., A.C.-W., R.S., L.S., D.C.M., M.J.B. Supervision: K.O.S., K.W., M.T., P.A., D.W.C., M.B., M.J.B., H.D., S.M.A., T.B., L.V., D.C.M., F.W.A., B.F.H., R.J.E., M.G.L., M.T., S.G.R. Data analysis: K.O.S., K.W., M.T., W.R., R.J.E., P.A., T.B., S.M.A., R.H., A.L.H., D.E., M.B., E.G., H.D., L.V., D.W.C., D.C.M., F.W.A., B.F.H. Writing: B.F.H., K.O.S., K.W., M.T., and P.A. with editing from all other co-authors.
    These authors contributed equally to this work
    Present address: San Diego Biomedical Research Institute, San Diego, CA 92121, USA.
    Author contributions
  • Descrição: Engineering better bnAbs A highly effective HIV vaccine has been the goal of vaccinologists for nearly 35 years. A successful vaccine would need to induce broadly neutralizing antibodies (bnAbs) that are capable of neutralizing multiple HIV strains (see the Perspective by Agazio and Torres). Steichen et al. report a strategy in which the first vaccine shot can lead to immune responses that generate desired bnAbs. By combining knowledge of human antibody repertoires and structure to guide design, they validated candidate immunogens through functional preclinical testing. Saunders et al. designed immunogens with differences in binding strength for bnAb precursors, which enabled selection of rare mutations after immunization. The immunogens promoted bnAb precursor maturation in humanized mice and macaques. Science , this issue p. eaax4380 , p. eaay7199 ; see also p. 1197 Engineering antibodies against rare HIV mutations is required for HIV neutralizing antibody development. INTRODUCTION A major goal of HIV-1 vaccine development is the design of immunogens that induce broadly neutralizing antibodies (bnAbs). However, vaccination of humans has not resulted in the induction of affinity-matured and potent HIV-1 bnAbs. To devise effective vaccine strategies, we previously determined the maturation pathway of select HIV-1 bnAbs from acute infection through neutralizing antibody development. During their evolution, bnAbs acquire an abundance of improbable amino acid substitutions as a result of nucleotide mutations at variable region sequences rarely targeted by activation-induced cytidine deaminase, the enzyme responsible for antibody mutation. A subset of improbable mutations is essential for broad neutralization activity, and their acquisition represents a key roadblock to bnAb development. RATIONALE Current bnAb lineage–based vaccine strategies can initiate bnAb lineage development in animal models but have not specifically elicited the improbable mutations required for neutralization breadth. Induction of bnAbs requires vaccine strategies that specifically engage bnAb precursors and subsequently select for improbable mutations required for broadly neutralizing activity. We hypothesized that vaccination with immunogens that bind with moderate to high affinity to bnAb B cell precursors, and with higher affinity to precursors that have acquired improbable mutations, could initiate bnAb B cell lineages and select for key improbable mutations required for bnAb development. RESULTS We elicited serum neutralizing HIV-1 antibodies in human bnAb precursor knock-in mice and wild-type macaques vaccinated with immunogens designed to select for improbable mutations. We designed two HIV-1 envelope immunogens that bound precursor B cells of either a CD4 binding site or V3-glycan bnAb lineage. In vitro, these immunogens bound more strongly to bnAb precursors once the precursor acquired the desired improbable mutations. Vaccination of macaques with the CD4 binding site–targeting immunogen induced CD4 binding site serum neutralizing antibodies. Antibody sequences elicited in human bnAb precursor knock-in mice encoded functional improbable mutations critical for bnAb development. In bnAb precursor knock-in mice, we isolated a vaccine-elicited monoclonal antibody bearing functional improbable mutations that was capable of neutralizing multiple HIV-1 global isolates. Structures of a bnAb precursor, a bnAb, and the vaccine-elicited antibody revealed the precise roles that acquired improbable mutations played in recognizing the HIV-1 envelope. Thus, our immunogens elicited antibody responses in macaques and knock-in mice that exhibited the mutational patterns, structural characteristics, or neutralization profiles of nascent broadly neutralizing antibodies. CONCLUSION Our study represents a proof of concept for targeted selection of improbable mutations to guide antibody affinity maturation. Moreover, this study demonstrates a rational strategy for sequential immunogen design to circumvent the difficult roadblocks in HIV-1 bnAb induction by vaccination. We show that immunogens should exhibit differences in affinity across antibody maturation stages where improbable mutations are necessary for the desired antibody function. This strategy of selection of specific antibody nucleotides by immunogen design can be applied to B cell lineages targeting other pathogens where guided affinity maturation is needed for a protective antibody response. Overcoming somatic mutation roadblocks to advance broadly neutralizing HIV-1 antibody (bnAb) development. Vaccination of animal models with engineered HIV-1 immunogens generated antibodies that acquired functional improbable mutations critical for virus neutralization. The lack of envelope selection of improbable mutations is a roadblock for bnAb development. Vaccine-elicited antibodies exhibited neutralization activity similar to that of intermediate-stage bnAbs. Structural studies showed a vaccine-elicited neutralizing antibody bound to HIV-1 envelope in a manner similar to that of a mature bnAb.
  • Editor: United States: The American Association for the Advancement of Science
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.